This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Adeno-associated virus-like particles
Description: Adeno-associated virus-like particles (AAVLP) are non-infectious and non-replicating protein particles. The virus protein shell, the capsid, is suited for the production of AAVLP, which can be used as a basis for novel vaccines. By inserting short antigenic peptides (B-cell epitopes) into the AAV capsid, a highly specific antibody reaction against selected target molecules can be induced. These antibodies can protect the body or act as a therapy against existing diseases.
Deal Structure: In May 2011, MediGene and The Johns Hopkins University have entered into a development collaboration with the objective of testing vaccine candidates derived from the AAVLP program for the prevention of HPV-associated cancer types, and in so doing to further advance the development of the AAVLP program.
AAVLP Vaccine News
Additional information available to subscribers only: